Program Overview
This CME activity will provide learners with an update regarding the treatment and management of patients with moderate-to-severe psoriasis. The expert faculty will review disease severity, comorbidities and patient-tailored treatment strategies of moderate-to-severe psoriasis. An analysis of how psoriasis treatment effects cardiovascular outcomes will be discussed. Recent clinical trial data of novel therapeutics for the treatment of psoriasis will also be reviewed. The faculty will discuss how to best develop patient-tailored treatment strategies to achieve optimal outcomes when treating patients with moderate-to-severe psoriasis. Upon completing this CME activity, clinicians will be better equipped to manage and treat their patients with psoriasis.
Target Audience
Dermatologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with psoriasis
Learning Objectives
1. Identify disease severity, comorbidities, and patient-tailored treatment strategies for moderate-to-severe psoriasis.
2. Analyze clinical trial data for novel therapeutics for the treatment of psoriasis.
3. Develop patient-tailored treatment strategies to achieve optimal outcomes in patients with moderate-to-severe psoriasis.
Faculty
Andrew Blauvelt, MD, MBA
President, Oregon Medical Research Center
Portland, Oregon
Jashin J. Wu, MD
Founder and CEO
Dermatology Research and Education Foundation
Irvine, California
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Faculty | Relationship Identified With: |
| Andrew Blauvelt, MD, MBA | Consultant/Advisor: AbbVie Inc.; Aclaris Therapeutics, Inc.; Akros Pharma Inc.; Allergan; Almirall; Amgen Inc.; Arena Pharmaceuticals; Boehrinher Ingelheim; Bristrol-Myers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; F. Hoffman-La Roche Ltd; FLX Bio, Inc.; Galderma; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Janssen Global Services. LLC; LEO Pharma Inc.; Meiji Holdings Co., Ltd.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Purdue Pharma L.P; Regeneron Pharmaceuticals; Revance Therapeutics, Inc.; Sandoz; Sienna Biopharmaceuticals; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Valeant Pharmaceuticals North America, LLC; VidacGrant/Research Support: AbbVie Inc.; Aclaris Therapeutics, Inc.; Akros Pharma Inc.; Allergan; Almirall; Amgen Inc.; Arena Pharmaceuticals; Boehrinher Ingelheim; Bristrol-Myers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; F. Hoffman-La Roche Ltd; FLX Bio, Inc.; Galderma; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Janssen Global Services. LLC; LEO Pharma Inc.; Meiji Holdings Co., Ltd.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Purdue Pharma L.P; Regeneron Pharmaceuticals; Revance Therapeutics, Inc.; Sandoz; Sienna Biopharmaceuticals; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Valeant Pharmaceuticals North America, LLC; VidacSpeaker’s Bureau: Genzyme Corporation; Janssen Global Services. LLC; Regeneron Pharmaceuticals |
|
Jashin J. Wu, MD
|
Consultant/Advisor: AbbVie Inc.; Almirall; Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; Dermira, Inc.; Dr. Reddy’s Laboratories Ltd.; Eli Lilly and Company, Janssen Global Services, LLC; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Promius Pharma, LLC.; Regeneron Pharmaceuticals; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Valeant Pharmaceuticals North America, LLCGrant/Research Support: AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Global Services, LLC; Novartis Pharmaceuticals CorporationSpeaker’s Bureau: AbbVie Inc.; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi-Aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Valeant Pharmaceuticals North America, LLC |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
